Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$16.07 - $31.84 $122,967 - $243,639
7,652 New
7,652 $221,000
Q2 2023

Aug 10, 2023

BUY
$20.94 - $38.01 $145,951 - $264,929
6,970 New
6,970 $250,000
Q3 2022

Nov 14, 2022

SELL
$43.66 - $61.0 $23,358 - $32,635
-535 Reduced 8.74%
5,585 $300,000
Q2 2022

Jul 19, 2022

BUY
$28.82 - $77.35 $8,242 - $22,122
286 Added 4.9%
6,120 $246,000
Q1 2022

May 04, 2022

BUY
$48.25 - $100.49 $15,343 - $31,955
318 Added 5.77%
5,834 $386,000
Q4 2021

Jan 31, 2022

BUY
$88.71 - $120.43 $32,024 - $43,475
361 Added 7.0%
5,516 $551,000
Q3 2021

Oct 29, 2021

SELL
$98.77 - $132.17 $48,496 - $64,895
-491 Reduced 8.7%
5,155 $644,000
Q2 2021

Aug 11, 2021

SELL
$109.77 - $165.68 $30,296 - $45,727
-276 Reduced 4.66%
5,646 $701,000
Q1 2021

May 04, 2021

BUY
$127.04 - $179.1 $60,725 - $85,609
478 Added 8.78%
5,922 $903,000
Q4 2020

Feb 11, 2021

SELL
$99.96 - $135.93 $180,927 - $246,033
-1,810 Reduced 24.95%
5,444 $701,000
Q3 2020

Nov 05, 2020

BUY
$80.32 - $111.8 $55,099 - $76,694
686 Added 10.44%
7,254 $810,000
Q2 2020

Aug 12, 2020

BUY
$60.49 - $97.5 $92,368 - $148,882
1,527 Added 30.29%
6,568 $532,000
Q1 2020

May 11, 2020

SELL
$59.04 - $88.81 $21,018 - $31,616
-356 Reduced 6.6%
5,041 $350,000
Q4 2019

Feb 05, 2020

SELL
$59.49 - $82.78 $21,059 - $29,304
-354 Reduced 6.16%
5,397 $421,000
Q3 2019

Oct 30, 2019

SELL
$62.59 - $110.3 $3,817 - $6,728
-61 Reduced 1.05%
5,751 $367,000
Q2 2019

Jul 19, 2019

BUY
$63.94 - $91.11 $120,399 - $171,560
1,883 Added 47.93%
5,812 $501,000
Q1 2019

May 13, 2019

BUY
$34.3 - $97.98 $134,764 - $384,963
3,929 New
3,929 $301,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.59B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.